期刊文献+

替加环素对比左氧氟沙星治疗社区获得性肺炎疗效与安全性的Meta分析 被引量:4

Comparative Efficacy and Safety of Tigecycline to Levofloxacin in the Treatment of Community Acquired Pneumonia: a Meta-analysis
下载PDF
导出
摘要 目的:系统评价替加环素与左氧氟沙星治疗社区获得性肺炎的疗效与安全性。方法:计算机检索The Cochrane library,Pub Med,Web of science,中国知网、万方数据库、维普期刊数据库,搜索替加环素对比左氧氟沙星治疗社区获得性肺炎的随机对照试验,并对获得的研究进行质量评价,综合纳入符合条件的文献用Rev Man 5.0统计学软件进行Meta分析。结果:共纳入3项RCT,合计1 275例患者,Meta分析结果显示,基于临床有效(CE)人群,替加环素对比左氧氟沙星治疗社区获得性肺炎(CAP)临床治疗有效率的差异无统计学意义(OR合并=1.40,95%CI[0.92,2.15],P=0.12);基于临床意向性分析(c-m ITT)人群,两组临床治疗有效率的差异无统计学意义(OR合并=1.11,95%CI[0.82,1.49],P=0.5),因此替加环素与左氧氟沙星相比治疗CAP效果相当。两组总不良反应发生率的差异有统计学意义(OR合并=1.57,95%CI[1.25,1.97],P<0.000 1),两组消化系统不良反应发生率的差异无统计学意义(OR合并=2.29,95%CI[1.75,3.01],P<0.000 01)。结论:本研究证据表明替加环素可以作为社区获得性肺炎的替代治疗药物,但与左氧氟沙星相比其不良反应风险会增加,治疗费用也会大大增加,不作为社区获得性肺炎的首选。本研究纳入的随机对照试验(RCT)质量高,但是数量较少,随着更多RCT的开展,结论将被进一步论证。 Objective:To evaluate the efficacy and safety of tigecycline vs levofloxacin for community-acquired pneumonia. Methods:Retrieved RCTs from The Cochrane library, PubMed, Web of science, CNKI, Wanfang database, VIP database. The quality of literature acquired was reviewed and eligible studies were included. Rev Man 5.0 statistical software was adopted for Meta-analysis. Results:A total 3 studies were included, involving 1275 patients. Meta-analysis showed that in the clinical efficacy rate analysis based on CE population (the combined OR = 1.40,95 % CI[ O. 92,2. 15 ] , P =0.12), in the clinical efficacy rate analysis based on c-mITY population( the combined OR = 1.11, 95% CI = 0. 82, 1.49, P = 0.5 ), the results were of no statistical difference, thus, there was no difference between tigeceycline and levo- floxacin in clinical efficacy. In the total adverse events frequency analysis (the combined OR = 1.57, 95% CI[ 1.25, 1.97 ], P 〈 0.000 1 ), In the adverse events frequency analysis on digestive system ( the combined OR = 2. 29, 95 % CI [ 1.75,3.01 ] ,P 〈 0.000 01 ), there were significant diferences between the two groups. Conclusion:The study revealed that tigecycline can be used as alternative medicine on CAP but with higher ADRs possibility, the quality of RCT brought into the study were high, but the quantity was less, the results will be further proved.
出处 《药物流行病学杂志》 CAS 2015年第10期577-581,共5页 Chinese Journal of Pharmacoepidemiology
关键词 替加环素 左氧氟沙星 社区获得性肺炎 META分析 Tigecycline Levofloxacin Community-acquired pneumonia Meta-analysis
  • 相关文献

参考文献10

  • 1Guti6rrez F, Masi6 M, Mirete C, et al. The influence of age and gender on the population-based incidence of community- acquired pneumonia caused by different microbial pathogens [J]. J lnfect, 2006, 53(3):166-174.
  • 2File TM Jr, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia [J]. Chest, 2004, 125(5) :1888-1901.
  • 3Fine MJ, Smith MA, Carson CA, et al. Prognosis and out- comes of patients with community-acquired pneumonia. A me- ta-analysis [ J ]. JAMA, 1996,275 (2) : 134-141.
  • 4Pankey CA. Tigeeycline[ J]. J Antimicrob Chemother, 2005, 56(3 ) :470-480.
  • 5Bradford PA, Petersen PJ, Tuckman M, et al. In vitro activi- ty of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complieated skin and skin structure infections and complicated intra-abdominal infections [ J ]. Clin Infect Dis ,2005,41 ( S5 ) :S315-S332.
  • 6Contte JE Jr, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline [ J ]. Int J Antimicrob Agents, 2005,25 (6) :523 -529.
  • 7Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin[ J ]. Diagn Microbiol Infect D/s, 2009, 63(1) :52-61.
  • 8Tanaseanu C, Milutinovic S, Calistru PI,et al. Efficacy and safety of tigecycline versus levofloxacin for community-ac- quired pneumonia[J]. BMC Pulm Med, 2009, 9:44.
  • 9Dartois N, Casting N, Grandjini A, et al. Tigecycline versuslevofloxaein for the treatment of community-acquired pneumo- nia: European Experience[J]. J Chemother, 2008, 20(sl ) : 28-35.
  • 10Jadad, AR, Moore RA, Carroll D, et al. Asssesing the qual- ity of reports of randomized clinical trials: is blinding neces- sary? [J]. Control Clin Trials, 1996,17(1) :1-12.

同被引文献46

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部